肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
11期
736-738
,共3页
恶性胸膜间皮瘤%培美曲塞%顺铂%药物疗法,联合%无进展生存期%生存期
噁性胸膜間皮瘤%培美麯塞%順鉑%藥物療法,聯閤%無進展生存期%生存期
악성흉막간피류%배미곡새%순박%약물요법,연합%무진전생존기%생존기
Malignant pleural mesothelioma%Pemetrexed%Cisplatin%Drug therapy,combination%Progression-free survival%Survival rate
目的 回顾分析培美曲塞(PEM)联合顺铂(DDP)治疗恶性胸膜间皮瘤(MPM)的疗效.方法 将64例MPM患者分为2组,PEM组(32例)予PEM联合DDP,DDP组予以单纯DDP.分析两组有效率、无进展生存期(DFS)及总生存期(OS).结果 两组患者化疗期间均未见明显不良反应,治疗后PEM组及DDP组有效率分别为56.25％(18/32)、21.88％(7/32),差异有统计学意义(x2=7.943,P＜ 0.05).PEM组较DDP组DFS延长(P=0.033).治疗后PEM组OS较DDP组高(P=0.041).结论 PEM联合DDP在延长MPM患者DFS及提高生存率方面有一定作用.
目的 迴顧分析培美麯塞(PEM)聯閤順鉑(DDP)治療噁性胸膜間皮瘤(MPM)的療效.方法 將64例MPM患者分為2組,PEM組(32例)予PEM聯閤DDP,DDP組予以單純DDP.分析兩組有效率、無進展生存期(DFS)及總生存期(OS).結果 兩組患者化療期間均未見明顯不良反應,治療後PEM組及DDP組有效率分彆為56.25％(18/32)、21.88％(7/32),差異有統計學意義(x2=7.943,P＜ 0.05).PEM組較DDP組DFS延長(P=0.033).治療後PEM組OS較DDP組高(P=0.041).結論 PEM聯閤DDP在延長MPM患者DFS及提高生存率方麵有一定作用.
목적 회고분석배미곡새(PEM)연합순박(DDP)치료악성흉막간피류(MPM)적료효.방법 장64례MPM환자분위2조,PEM조(32례)여PEM연합DDP,DDP조여이단순DDP.분석량조유효솔、무진전생존기(DFS)급총생존기(OS).결과 량조환자화료기간균미견명현불량반응,치료후PEM조급DDP조유효솔분별위56.25％(18/32)、21.88％(7/32),차이유통계학의의(x2=7.943,P＜ 0.05).PEM조교DDP조DFS연장(P=0.033).치료후PEM조OS교DDP조고(P=0.041).결론 PEM연합DDP재연장MPM환자DFS급제고생존솔방면유일정작용.
Objective To explore the clinical efficacy of ALIMTA (pemetrexed disodium) plus cisplatin.Methods Patients with malignant mesothelioma were allocated to two treatment groups envelope:pemetrexed plus cisplatin (PEM-group) or cisplatin alone (DDP-group).Results A total of 64 patients were randomly assigned and evaluated.The number of patients in PEM- and DDP-group had a significant pathologic complete response were (56.25 ％ vs 21.88 ％,x2 =7.943,P ＜0.05).Progression-free survival was significantly higher in PEM-group (P ＜0.05),and 2-year survival rate was lower in DDP-group (P ＜0.05).Conclusion Pemetrexed elicit significant tumor response and delays disease progression compared with DDP alone in patients with advanced MPM.Improvement in OS is seen in this study.
